Chimerix continuously seeks to access external innovation where it can help speed the development of potential life-saving medicines to patients while creating long-term value. With a focus on extending patients’ lives who are suffering from life-threatening diseases, we have specific interest in partnering for clinical-stage assets in virology and oncology where we can leverage our substantial expertise. For more information about our interests and how we might work together to advance innovation, please contact Mike Andriole, Chief Business Officer, at mandriole@chimerix.com.

Key benefits of collaborating with Chimerix include:

  • Strong culture of innovation
  • Extensive clinical development and regulatory experience
  • Commercial group with proven track record of successful product launches
  • Creativity in constructing partnerships
  • Commitment to professional alliance management
  • Public company infrastructure

BARDA

In 2011, Chimerix initiated a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir (CMX001) as a medical countermeasure to treat smallpox outbreaks due to a bioterror event or accidental release. Brincidofovir has received Fast Track designation from the FDA for smallpox, adenovirus and cytomegalovirus.